Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study

J Am Acad Dermatol. 2024 Jun;90(6):1254-1256. doi: 10.1016/j.jaad.2024.01.025. Epub 2024 Jan 28.

¹ Probity Medical Research and Alliance Clinical Trials, Waterloo, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada.
² Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Skin Health & Wellness Centre, Calgary, Alberta, Canada; Probity Medical Research, Calgary, Alberta, Canada.
³ Department of Dermatology and Skin Science, University of Montreal, Montreal, Quebec, Canada; Innovaderm Research Inc, Montreal, Quebec, Canada.
⁴ Bausch Health Companies, Laval, Quebec, Canada.
⁵ Bausch Health Companies, Laval, Quebec, Canada. Electronic address: maxime.barakat@bauschhealth.com.
⁶ Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Dermatrials Research Inc, Hamilton, Ontario, Canada.

No abstract available

Keywords: Psoriasis Area and Severity Index; biologic; biologic failure; brodalumab; plaque psoriasis; switch.

Publication types